An emerging challenge: tki-induced cardiovascular adverse events in cml patients
| dc.contributor.advisor | Batár, Péter | |
| dc.contributor.advisordept | Internal Medicine 2nd Department | hu_HU |
| dc.contributor.author | Abodunrin, Faith Opeyemi | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Bodor, Miklós | |
| dc.contributor.opponent | Reményi, Gyula | |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézet | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézet | hu_HU |
| dc.date.accessioned | 2020-02-24T11:06:24Z | |
| dc.date.available | 2020-02-24T11:06:24Z | |
| dc.date.created | 2019-03-05 | |
| dc.description.abstract | The development and introduction of tyrosine kinase inhibitors (TKIs) marked a huge turning point in the treatment of chronic myeloid leukemia patients. Different adverse events have been encountered with the use of TKIs over the years. TKI-induced cardiovascular adverse events, in particular, are a cause of growing concern in CML therapy. Several studies reporting these cardiovascular adverse events have been conducted over the years. Current evidence largely shows that imatinib, a first-generation TKI is the least toxic to the cardiovascular system. Second and third-generation TKIs like dasatinib, nilotinib, and ponatinib, however, have a higher cardiovascular impact as several cases of cardiovascular adverse events have been reported with their use. In this review, we will present preliminary results from a retrospective analysis carried out at our institution. In addition, we will discuss the available evidence on the TKI-associated cardiovascular adverse events reported in the literature. Proposed clinical recommendations regarding risk modification, surveillance, and management of these adverse events will also be presented. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 52 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/281208 | |
| dc.language.iso | en | hu_HU |
| dc.subject | TKI | hu_HU |
| dc.subject | Tyrosine kinase inhibitors | hu_HU |
| dc.subject | Chronic Myeloid Leukemia | hu_HU |
| dc.subject | Cardiovascular Complications | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | An emerging challenge: tki-induced cardiovascular adverse events in cml patients | hu_HU |